Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer’s disease (AD) agitation...
Barchart Research What to Expect from NMRA Earnings NMRA Generated August 11, 2026 Current Price $1.7000 EPS Estimate $$-0.23 Consensus Rating Moderate Buy Average Move 8.92% Neumora's Depression Drug...
Barchart Research What to Expect from NMRA Earnings NMRA Generated August 4, 2026 Current Price $1.6000 EPS Estimate $$-0.23 Consensus Rating Moderate Buy Average Move 8.92% Neumora: Can Restarted Trials...
WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target...
Neumora Therapeutics projected cash runway "into 2027" tied to clinical milestones that never materialized -- then cut 35% of its workforce the same day both pivotal trials failed.
Neumora Therapeutics characterized its first failed Phase 3 trial as an "anomaly" and projected 90% statistical power across its navacaprant program -- then both remaining pivotal trials failed, triggering...
Neumora Therapeutics reported data from its Phase 3 KOASTAL Program; the stock fell nearly 50%.
Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease...
SoftBank fully exited Circle Internet Group in Q1 2026. Here is what investors need to know about the stablecoin giant's fundamentals.
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target...